A Phase 3 interventional study of Hylastan in Osteoarthritis, Knee, sponsored by Genzyme, a Sanofi Company. Completed at 24 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2014-02-05.
Sponsored by Genzyme, a Sanofi Company · Phase 3, Interventional, and Treatment
This is a clinical study to investigate the safety and efficacy of hylastan in treating patients with symptomatic osteoarthritis (OA) of the knee.
4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.
Browse Osteoarthritis studies →Genzyme, a Sanofi Company is the lead sponsor of 303 studies on the registry; 5 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 19 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
pain relief
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genzyme, a Sanofi Company